Literature DB >> 28728440

Rituximab subcutaneous in B-cell non-Hodgkin lymphoma: clinical experience in a single center.

Blanca Sanchez-Gonzalez1,2, Elena Torres1, Mariana Paola Ferraro Rosset1, Montserrat Calafell1, Carmen Gale1, Laia Martinez1, Esther Sancho1, Pilar Garcia1, Eva Gimeno1, Francesc Garcia-Pallarols1, Antonio Salar1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28728440     DOI： 10.1080/10428194.2017.1349906

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  2 in total

1.  Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.

Authors:  Ricardo García-Muñoz; Cristina Quero; Ernesto Pérez-Persona; Abel Domingo-García; Cristina Pérez-López; Teresa Villaescusa-de-la-Rosa; Ana M Martínez-Castro; José M Arguiñano-Pérez; Juan F Parra-Cuadrado; Carlos Panizo
Journal:  Br J Haematol       Date:  2019-10-01       Impact factor: 6.998

2.  Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.

Authors:  Mario Petrini; Gianluca Gaidano; Andrea Mengarelli; Ugo Consoli; Armando Santoro; Anna Maria Liberati; Marco Ladetto; Vincenzo Fraticelli; Attilio Guarini; Donato Mannina; Paola Ferrando; Paolo Corradini; Pellegrino Musto; Caterina Stelitano; Dario Marino; Andrea Camera; Marco Murineddu; Roberta Battistini; Giuseppe Caparrotti; Mauro Turrini; Luca Arcaini; Simone Santini; Manuela Cerqueti; Andres J M Ferreri; Nicola Cantore; Alessandro Inzoli; Giovanni Cardinale; Benedetto Ronci; Giorgio La Nasa; Stefano Massimi; Gianfranco Gaglione; Valentina Barbiero; Maurizio Martelli
Journal:  Adv Hematol       Date:  2022-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.